The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Treatment approaches for BRAF V600E mutant metastatic colorectal cancer
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, highlights current treatment strategies for metastatic colorectal cancer. For patients with BRAF V600E mutations, treatment varies by mismatch repair (MMR) status. For proficient MMR (pMMR) tumors, the BEACON CRC trial (NCT02928224) supports using encorafenib plus cetuximab, with other ongoing trials evaluating nivolumab. For deficient MMR (dMMR) tumors, the SEAMARK trial (NCT05217446) shows promising results for pembrolizumab combined with encorafenib and cetuximab. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
